Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email

R3i PUBLICATIONS

2014

Residual Microvascular Risk in Type 2 Diabetes in 2014: Is it Time for a Re-Think? A Perspective from the Residual Risk Reduction Initiative (R3i)

Michel P Hermans, Jean-Charles Fruchart, Jean Davignon, more....

Microvascular complications associated with type 2 diabetes, including diabetic retinopathy, nephropathy and neuropathy, account for much of the societal burden of diabetes. Even with effective multifactorial intervention, targeting glycemia, blood pressure and lowdensity lipoprotein cholesterol, in addition to lifestyle intervention, a high residual microvascular risk persists. The Residual Risk Reduction Initiative (R3i) highlights two key priorities for reducing this residual risk. First, there should be optimal management of cardiometabolic risk factors, including atherogenic dyslipidemia, elevated triglycerides and low plasma high-density lipoprotein cholesterol, to improve lipid goal attainment. Second, consistent evidence from two major trials may merit consideration of adjunctive fenofibrate therapy to slow progression of diabetic retinopathy in type 2 diabetes patients with pre-existing disease. These data provide a strong rationale for testing in a prospective study. The R3i strongly believes that addressing both priorities is critical to reducing the substantial residual risk of microvascular complications in type 2 diabetes.

Residual macrovascular risk in 2013: What have we learned?

Jean-Charles Fruchart, Jean Davignon, Michel P. Hermans, more....

The International Steering Committee of the Residual Risk Reduction Initiative (R3i), comprising 40 leading specialists from North and South America, Europe, the Middle East, Asia and Japan, has today highlighted priorities for action against atherogenic dyslipidaemia, an important contributor to lipid-related residual cardiovascular risk. The R3i defines atherogenic dyslipidaemia as the imbalance between triglyceride-rich apolipoprotein B-containing-lipoproteins, for which triglycerides are a marker, and apolipoprotein A-I-lipoproteins (as in high-density lipoprotein, HDL).   The R3i has identified three key priorities: • To improve recognition of atherogenic dyslipidaemia in high risk patients, including those with diabetes • To target atherogenic dyslipidaemia, using non-HDL cholesterol (total cholesterol – HDL cholesterol) for treatment decisions • To improve management of atherogenic dyslipidaemia, and adherence to guideline-recommended therapies. The addition of a fibrate, niacin (North and South America), omega-3 fatty acids or ezetimibe to statin therapy are all approaches to reduce non-HDL cholesterol.   The R3i recognises that there is a need for new treatment options that can more effectively target atherogenic dyslipidaemia, and reviews future possibilities in this paper. This paper will have important implications for the routine management of patients who remain at high residual cardiovascular risk despite well controlled low-density lipoprotein (LDL) cholesterol levels
2013

Association Between Plasma Triglycerides and HDL-cholesterol and Microvascular Nephropathy and Retinopathy in Type 2 Diabetes: A global case:control study in 13 countries

Frank M. Sacks, Michel P. Hermans, Paola Fioretto, more....

2012

Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial

G. Reyes-Soffer, C Ngai, L Lovato, more....

This ancillary study evaluated postprandial lipaemia after an oral fat test in a subgroup of patients in the ACCORD Lipid study. Fenofibrate treatment reduced postprandial exposure to atherogenic apolipoprotein B48 only in patients with elevated fasting triglycerides at baseline. This suggests that fenofibrate improves clearance of atherogenic triglyceride-rich remnant lipoproteins and reduces residual macrovascular risk in type 2 diabetes patients, only if fasting levels are sufficiently increased at baseline.
2011

PCSK9: the functional relevance of fenofibrate-statin combination therapy to reduce residual cardiovascular risk

JC Fruchart International Journal of Diabetes Mellitus

The author reminds the physiology and roles of PCSK9, notably in the regulation of LDL-C levels through its ability to target the LDL-C receptor. Then, he describes the way statins and fibrates, notably fenofibrate, act on PCSK9. Finally, he concludes that the existing data (1) provide a functional rationale for the combination of fenofibrate with a statin for optimizing LDL-C lowering efficacy, (2) suggest that PSCK9 may be a potential target in patients with type 2 diabetes or metabolic syndrome, opening new approaches that could impact the substantial residual cardiovascular risk that exists in statin-treated patients.

Does microvascular disease predict macrovascular events in type 2 diabetes

RS Rosenson, P Fioretto, PM Dodson Atherosclerosis

This review, based on 25 studies including 54,117 patients highlights the association between micro- and macrovascular disease in type 2 diabetes, underlining the importance of early detection of microangiopathy for vascular risk assessment in type 2 diabetes.
2010

Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction initiative (R3i) Current Medical Research and Opinion

Fruchart JC, Sacks FM, Hermans MP

Discussing the ACCORD Lipid study results, this commentary concludes that they suggest that dyslipidemia management in type 2 diabetes requires a targeted approach based on the lipid profile of individual patients. In particular, in statin-treated patients with atherogenic dyslipidemia, adding fenofibrate can provide additional reduction in cardiovascular risk.

Non-LDL-related dyslipidaemia and coronary risk: a case-control study

Assmann G, Cullen P, Schulte H. Diabetes and Vascular Disease Research

To assess the non-LDL-C-related dyslipidaemia risk of MI, 823 men aged 23 to 65 with a first MI were compared with 823 MI-free PROCAM controls matched for sex, age, smoking, DM, BP and LDL-C. This case-control study has two main findings: first, dyslipidemia is associated with the greatest increase in relative risk of MI in persons with low levels of LDL-C; second, low HDL-C makes a greater contribution to MI risk than do high TG once other conventional MI risk factors are accounted for.

Combination lipid therapy in type 2 diabetes (correspondence)

Sacks FM, Carey VJ, Fruchart JC New England Journal of Medicine

Based on a meta-analysis of 5 trials (FIELD, BIP, HHS, VA-HIT and ACCORD), the authors conclude that fibrate treatment reduces coronary heart disease events among patients with dyslipidemia.
2009

Residual microvascular risk in diabetes: unmet needs and future directions

Fioretto P, Dodson PM, Ziegler D, more....

In this review, the authors highlight an urgent need to address the residual microvascular risk that remains high in patients with type 2 diabetes mellitus even if they receive optimal management according to current standards of care. They also conclude that correction of atherogenic dyslipidemia might provide additional benefit.
2008

R3i Position Paper

Jean-Charles Fruchart PhD, Frank Sacks MD, Michel P. Hermans MD PhD, more....

The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in dyslipidemic patients